BioT (BTMD) Q4 2025: Sales Force Expands 33% as Clinic Attrition Stabilizes, Setting Stage for H2 Recovery
BioT’s Q4 revealed a business in operational transition, with procedure revenue under pressure but early signals of stabilization emerging as commercial investments ramp. Management is betting on a 33% expansion in sales headcount and a revamped tech platform to reverse clinic attrition and reignite procedure growth in the second half of 2026. Near-term margin and EBITDA compression reflect the cost of this pivot, but full training classes and improving practitioner engagement offer cautious optimism for a return to growth.
Summary
- Clinic Attrition Moderation: Early signs of stabilization in clinic churn following sales force rebuild.
- Growth Investment Inflection: 2026 will see a 33% increase in sales headcount and major tech platform upgrades.
- Second Half Reacceleration: Management targets resumed procedure growth and margin recovery by H2 2026.
Performance Analysis
BioT’s Q4 results paint a picture of a business navigating a challenging transition period, with total revenue declining as procedure volumes fell and clinic attrition remained elevated. Procedure revenue, the core annuity-like stream derived from hormone replacement therapy (HRT) procedures performed at partner clinics, dropped sharply, driven primarily by fewer net new clinic additions and persistent volume softness. Dietary supplement revenue, a smaller but growing component, provided a partial offset with double-digit growth fueled by e-commerce channel gains.
Margins compressed materially, primarily due to a $1.3 million inventory charge tied to a voluntary product recall and a heavier mix of third-party manufacturing. Excluding this charge, vertical integration via the Asteria facility and cost discipline did yield some efficiency gains, but not enough to counteract volume-driven deleverage. Operating expenses declined on lower legal costs and temporary headcount reductions, but the company flagged that this is a transient benefit as new hiring accelerates in 2026.
- Procedure Volume Drag: Volume contraction tied to above-normal clinic attrition in 2024, with stabilization only emerging late in Q4.
- Dietary Supplement Tailwind: 16% revenue growth in supplements reflects successful e-commerce execution, now a key complementary pillar.
- Margin Compression from Recall: Gross margin fell to 68% due to the recall, with risk of further pressure if third-party sourcing persists.
Net income and adjusted EBITDA both declined, with margin contraction reflecting both the revenue drag and the deliberate reinvestment cycle now underway. Cash flow from operations remained positive, supporting the planned commercial and technology investments for 2026.
Executive Commentary
"2025 was a pivotal and productive year for BioT, marked by important changes to the BioT team, our processes, and our culture. Through our decisive actions, we achieved progress against our strategic plan, and I believe we became a more resilient, more disciplined, and more effective organization."
Brett Christensen, Chief Executive Officer
"Dietary supplement revenue increased 16% to $11.7 million, primarily driven by the continued growth of our e-commerce channels. Dietary supplements represent an important and complementary market growth opportunity, strengthening patient engagement with BioT by meeting their evolving needs for safe and effective healthy aging solutions."
Bob Peterson, Chief Financial Officer
Strategic Positioning
1. Commercial Team Overhaul and Expansion
BioT has rebuilt its commercial organization, expanding sales headcount from 60 to over 90 in 2025 and targeting 120 by the end of Q1 2026—a 33% increase. This investment is designed to both stabilize clinic attrition and drive new clinic additions, with a focus on practitioner training and support as leading indicators for future procedure growth.
2. Technology Platform Investment
Significant capital is being allocated to upgrading the practitioner technology platform, aiming to streamline the end-to-end journey from training to clinic operation. Leadership sees this as critical to enhancing retention, boosting productivity, and supporting cross-sell of dietary supplements. Development will leverage both internal and external resources to address identified customer pain points.
3. Vertical Integration and Product Mix Management
The Asteria manufacturing facility, BioT’s 503B compounding site, remains central to margin strategy. The voluntary recall and resulting inventory charge highlighted the risks of third-party sourcing, but management is committed to restoring Asteria utilization above the current 50% share and regaining supply chain control to support gross margin recovery.
4. Data-Driven Practitioner and Clinic Retention
BioT has implemented analytics-driven contract and incentive models to reduce unanticipated attrition among top-performing clinics. This approach is paired with a new incentive compensation structure for the sales team, aligning performance with growth objectives and embedding accountability across the organization.
5. Diversification Through Dietary Supplements
Dietary supplements have emerged as a key growth lever, delivering 16% YoY growth and increasing their share of overall revenue. The e-commerce channel is now a proven route to deepen patient engagement and offset cyclical swings in procedure volume.
Key Considerations
This quarter marks a strategic inflection for BioT, as management pivots from defensive cost control to proactive growth investment. The effectiveness of these initiatives will determine whether the business can return to sustained top-line expansion and margin improvement in the coming quarters.
Key Considerations:
- Sales Force Ramp Timeline: New hires require six to nine months to reach full productivity, creating a lag before revenue impact materializes.
- Attrition Stabilization Remains Key: Clinic attrition, which spiked to high single digits in 2024, must remain contained to support any volume recovery.
- Recall and Supply Chain Risk: The voluntary recall and reliance on third-party manufacturing present near-term margin and revenue headwinds.
- Dietary Supplement Growth Sustainability: Continued double-digit growth in supplements will be vital to offsetting procedure volatility and supporting margin mix.
Risks
BioT faces execution risk in scaling its commercial team and achieving projected practitioner productivity, especially given the lag between hiring and revenue realization. Recall-related supply chain disruption and the risk of further gross margin pressure from third-party sourcing remain acute. Regulatory scrutiny in HRT and competitive responses to BioT’s renewed commercial push could also impact both volume and pricing power. Investors should monitor for signs of persistent attrition, delays in Asteria ramp, or muted practitioner engagement post-training.
Forward Outlook
For Q1 2026, BioT management expects:
- Procedure revenue to decline at a mid to high single-digit rate YoY, reflecting lingering attrition and recall impacts.
- Dietary supplement revenue to grow at a mid to high single-digit rate versus 2025.
For full-year 2026, management guided:
- Revenue above $190 million.
- Adjusted EBITDA greater than $38 million, down from 2025 due to planned investments.
Management emphasized that procedure revenue growth is expected to resume in the second half of 2026, with margin improvement tied to increased Asteria utilization and full ramp of the expanded sales force. Key watchpoints include attrition stabilization, practitioner productivity post-training, and recovery in gross margin as recall effects subside.
Takeaways
BioT’s 2026 outlook hinges on operational execution, with a bold bet on sales and technology investments to reverse recent headwinds. The balance of risk and reward will be dictated by the company’s ability to translate full training classes and an expanded sales force into durable volume growth and improved clinic retention.
- Sales and Tech Investment Cycle: The near-term margin and EBITDA compression reflects a deliberate pivot to growth, with returns expected in H2 2026 as new hires mature and platform improvements take hold.
- Attrition and Recall Mitigation: Stabilizing clinic churn and restoring Asteria’s manufacturing share are critical to both top-line and margin recovery.
- Watch for Productivity Inflection: Practitioner productivity following full training classes and new incentive structures will be the leading indicator for a true revenue turnaround.
Conclusion
BioT enters 2026 at a strategic crossroads, investing heavily in commercial and technology infrastructure after a year of attrition-driven contraction. Success will depend on the company’s ability to convert these investments into renewed procedure volume growth and sustained margin improvement, with the second half of the year as the critical proving ground.
Industry Read-Through
BioT’s experience underscores the operational sensitivity of annuity-based healthcare models to practitioner and clinic churn, especially when growth is tied to distributed provider networks. The recall-driven margin hit and reliance on vertical integration at Asteria highlight supply chain control as a competitive differentiator in regulated therapeutic markets. The shift to e-commerce for dietary supplements signals a broader trend of wellness platforms diversifying revenue streams beyond core procedures to mitigate cyclicality. For peers in hormone therapy, aesthetics, and therapeutic wellness, investments in practitioner enablement and digital engagement will be increasingly vital to sustaining growth and retention as regulatory and market dynamics evolve.